Article
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Leukemia - 1 Jan 2018
Brown J R, Hillmen P, O'Brien S, Barrientos J C, Reddy N M, Coutre S E, Tam C S, Mulligan S P, Jaeger U, Barr P M, Furman R R, Kipps T J, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel J M, Munir T, Burger J A, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James D F, Byrd J C
Abstract excerpt
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these traditionally chemotherapy resistant high-risk genomic subgroups at a median follow-up of 19 months. Mutations were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.